Lumos Pharma Stock Fundamentals
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos |
Lumos Pharma Company Return On Asset Analysis
Lumos Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lumos Pharma Return On Asset | -0.7 |
Most of Lumos Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Lumos Pharma has a Return On Asset of -0.6964. This is 92.04% lower than that of the Biotechnology sector and 97.05% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Lumos Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lumos Pharma's current stock value. Our valuation model uses many indicators to compare Lumos Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lumos Pharma competition to find correlations between indicators driving Lumos Pharma's intrinsic value. More Info.Lumos Pharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lumos Pharma's earnings, one of the primary drivers of an investment's value.Lumos Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in return on asset category among its peers.
Lumos Fundamentals
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Shares Owned By Insiders | 32.69 % | |||
| Shares Owned By Institutions | 24.27 % | |||
| Number Of Shares Shorted | 54.33 K | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X | |||
| Price To Sales | 17.02 X | |||
| Revenue | 2.05 M | |||
| Gross Profit | 1.52 M | |||
| EBITDA | (36.57 M) | |||
| Net Income | (34.03 M) | |||
| Cash And Equivalents | 79.51 M | |||
| Cash Per Share | 9.49 X | |||
| Total Debt | 585 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.59 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (31.09 M) | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (4.28) X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 4.25 | |||
| Number Of Employees | 30 | |||
| Beta | 0.33 | |||
| Market Capitalization | 37.54 M | |||
| Total Asset | 40.64 M | |||
| Retained Earnings | (161.52 M) | |||
| Working Capital | 33.01 M | |||
| Current Asset | 115.78 M | |||
| Current Liabilities | 14.4 M | |||
| Net Asset | 40.64 M |
Pair Trading with Lumos Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ConocoPhillips could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ConocoPhillips when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ConocoPhillips - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ConocoPhillips to buy it.
The correlation of ConocoPhillips is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ConocoPhillips moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ConocoPhillips moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ConocoPhillips can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |